戈沙妥珠单抗 (Trodelvy)

概览

Sacituzumab govitecan is sacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.

作用机制

The entrapment of SN-38 in lipsomes results in a more stable and more soluble form of the drug. This allows for increased affinity of SN-38 to lipid membranes and improved delivery of the drug to tumor sites. SN-38 is a highly effective cytotoxic topoisomerase I inhibitor.

适应症

Investigated for use/treatment in colorectal cancer.

• Hormone Receptor Positive Metastatic Breast Cancer
• Locally Advanced or Metastatic Urothelial Carcinoma (UC)
• Metastatic Triple Negative Breast Cancers
• Unresectable Triple-Negative Breast Carcinoma
• Metastatic HR Positive, HER2/Neu Negative Breast Cancer
• Unresectable Locally Advanced Triple-negative Breast Cancer
• Unresectable, locally advanced HR Positive, HER2/Neu Negative Breast Cancer
• Unresectable, locally advanced Hormone Receptor Positive Breast Carcinoma